{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"The MTD was defined as the safe dose level established in Lead-In Part. MTD was determined by summarizing the number and percentage of participants with DLTs for the first cycle, by study dosing schedule, initial dosing level and overall for the Lead-In Part.","groups":[{"description":"Participants were treated with E7777 6, 9, 12 and 15 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-In part.","id":"OG000","title":"Lead-In Part: E7777"}],"paramType":"NUMBER","populationDescription":"Dose-finding analysis set included all participants in the Lead-in part who completed Cycle 1 treatment and were evaluated for DLT, and those who discontinued during Cycle 1 due to DLT.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (cycle length was 21 days)","title":"Lead-In Part: Maximum Tolerated Dose (MTD) of E7777","type":"PRIMARY","unitOfMeasure":"mcg/kg"}